MIRA INFORM
REPORT
|
Report Date : |
02.04.2011 |
IDENTIFICATION DETAILS
|
Name : |
BENTA SAL |
|
|
|
|
Registered Office : |
|
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
31.12.2010 |
|
|
|
|
Year of Establishment : |
2004 |
|
|
|
|
Com. Reg. No.: |
2002750, Baabda |
|
|
|
|
Legal Form : |
Lebanese Joint Stock Company |
|
|
|
|
Line of Business : |
Production of pharmaceutical preparations |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal commitments. |
Satisfactory |
|
Maximum Credit Limit : |
US$ 250,000 |
|
Status : |
Satisfactory |
|
Payment
Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – December 31, 2010
|
Country Name |
Previous Rating (30.09.2010) |
Current Rating (31.12.2010) |
|
|
c1 |
c1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
SUMMARY
Company Name : BENTA SAL
Also Known As : BENTA PHARMACEUTICAL INDUSTRIES (BPI)
Country of Origin :
Legal Form : Lebanese Joint Stock Company
Registration Date : 2004
Commercial Registration Number : 2002750, Baabda
Issued Capital : LP 105,000,000
Paid up Capital : LP 105,000,000
Total Workforce : 100
Activities : Production of pharmaceutical preparations.
Financial Condition : Fair
Payments : Nothing detrimental uncovered
Operating Trend : Steady
Recommended Credit Limit : US$ 250,000
COMPANY NAME
BENTA SAL
ALSO KNOWN AS
BENTA PHARMACEUTICAL INDUSTRIES
(BPI)
company ADDRESS
Registered & Physical Address
Building :
Street : Street No. 104
Area : Zouk
El Khrab Area, Sin El Fil
PO Box : 55191
Town : Dbayeh
Country :
Telephone : (961-4) 541444
Facsimile : (961-4) 541333
Email : info@benta.com.lb
Premises
Subject operates
from a medium sized suite of offices and a factory that are owned and located in
the Suburban Business Area of Dbayeh.
KEY PRINCIPALS
Name Position
·
Bernard A Tannoury Managing
Director
·
Naji A Tannoury Director
·
Albert R Tannoury Director
·
·
Roula
Assily Finance
Manager
·
Nada
Ziade Human
Resources Manager
·
Walid
Alameddine Marketing
Manager
·
Charles
Khoury Sales
Manager
·
Elie
Bacha Purchasing
Manager
LEGAL FORM & OWNERS
Date of Establishment : 2004
Legal Form :
Lebanese Joint Stock
Company
Commercial Reg. No. : 2002750, Baabda
Issued Capital : LP 105,000,000
Paid up Capital : LP 105,000,000
Name of Shareholder
(s)
·
Bernard A Tannoury
·
Naji A Tannoury
·
Albert R Tannoury
OPERATIONS
Activities: Engaged in the production of pharmaceutical preparations, including cardiovascular
products, stimulants and anti-depressive agents for the central nervous system,
pharmaceutical preparations for metabolism, and oncological preparations.
Import
Countries: France, Italy, Germany, Greece, Spain, Switzerland,
Austria, Sweden, Ireland, Japan, Thailand,
South Korea, Canada, Mexico and the United States of America
Brand Names: GLISODIN,
SUCCAREL, ATORLIP, BECAPLEX, BISOCOR, CAPEDA, DIANORM, DURALIS,
GABRIKA, GEMTABINE, IVIRON, PIODIAB, PROSMIDE, RABEZOL,
TELMICARD, TRITACE and VENLAX
Operating Trend: Steady
Subject has a
workforce of approximately 100 employees.
FINANCIAL DATA
Financial
highlights provided by local sources are given below:
Currency: Lebanese
Pounds (LP)
Year
Ending 31/12/09: Year
Ending 31/12/10:
Total Sales LP 6,850,000,000 LP 7,200,000,000
Local sources
consider subject’s financial condition to be Fair.
The above financial
figures are based on estimations by our local sources.
BANKERS
·
Byblos
Bank Sal
PO Box: 115605
Tel: (961-1) 898200
Fax: (961-1) 898209
·
Credit
Bancaire Sal
PO Box: 165795
Tel: (961-1) 218183 / 200489
Fax: (961-1) 200483
·
HSBC
Bank
PO Box: 111380
Tel: (961-1) 425296
Fax: (961-1) 425295
PAYMENT HISTORY
No complaints
regarding subject’s payments have been reported.
GENERAL COMMENTS
During the course
of this investigation nothing detrimental was uncovered regarding subject’s
operating history or the manner in which payments are fulfilled. As such the
company is considered to be a fair trade risk.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.44.65 |
|
|
1 |
Rs.71.93 |
|
Euro |
1 |
Rs.63.24 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.